Skip to main content
Top
Published in: Digestive Diseases and Sciences 4/2024

15-02-2024 | Helicobacter Pylori | Original Article

Influence of Helicobacter pylori Infection and Eradication on Small Intestinal Bacterial Overgrowth and Abdominal Symptoms

Authors: Xiaolei Wang, Die Zhu, Siyu Li, Yun Dai, Guigen Teng, Weihong Wang

Published in: Digestive Diseases and Sciences | Issue 4/2024

Login to get access

Abstract

Background

The relationship between Helicobacter pylori (H. pylori) infection and small intestinal bacterial overgrowth (SIBO) has attracted attention recently.

Aims

To analyze the influence of H. pylori infection and eradication on SIBO, IMO, and abdominal symptoms.

Methods

Patients with gastrointestinal symptoms were tested for 13C urea breath test and if positive, treated with bismuth-based quadruple therapy. Lactulose hydrogen methane breath test (HMBT) was performed and symptoms were assessed using gastrointestinal symptom rating scale (GSRS) before and 6 weeks after eradication.

Results

Of the 102 subjects, 53 were H. pylori positive. The prevalence of SIBO and IMO were higher in patients with H. pylori infection than in those without infection (49.1% vs 24.5%, P = 0.019 for SIBO; 24.5% vs 8.2%, P = 0.027 for IMO). GSRS scores were similar between H. pylori-infected and uninfected patients (2 (IQR: 1;3) vs 2 (IQR: 1;2), P = 0.211). Patients with SIBO or IMO presented higher GSRS scores than patients with both SIBO and IMO negative (2 (IQR: 2;3), 2 (IQR: 2;3) vs 2 (IQR: 1;2), P = 0.011, 0.001, respectively). For the 50 patients who successfully eradicated H. pylori, the response rates for SIBO and IMO were 66.7% and 76.9%, respectively. GSRS scores also significantly decreased (2 (IQR: 1;3) to 0 (IQR: 0;1), P < 0.001) after eradication.

Conclusion

Helicobacter pylori infection was associated with higher prevalence of SIBO and IMO, both of which led to more pronounced abdominal symptoms. H. pylori eradication also achieved therapeutic effects on SIBO and IMO, accompanied by relief of abdominal symptoms.
Appendix
Available only for authorised users
Literature
2.
go back to reference Dore MP, Pes GM, Bassotti G, Usai-Satta P. Dyspepsia: when and how to test for Helicobacter pylori infection. Gastroenterol Res Pract 2016;2016:8463614.CrossRefPubMedPubMedCentral Dore MP, Pes GM, Bassotti G, Usai-Satta P. Dyspepsia: when and how to test for Helicobacter pylori infection. Gastroenterol Res Pract 2016;2016:8463614.CrossRefPubMedPubMedCentral
3.
go back to reference Ghoshal UC, Shukla R, Ghoshal U. Small intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomy. Gut Liver 2017;11:196–208.CrossRefPubMedPubMedCentral Ghoshal UC, Shukla R, Ghoshal U. Small intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomy. Gut Liver 2017;11:196–208.CrossRefPubMedPubMedCentral
4.
go back to reference Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol 2020;115:165–178.CrossRefPubMed Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol 2020;115:165–178.CrossRefPubMed
5.
go back to reference Massey BT, Wald A. Small intestinal bacterial overgrowth syndrome: a guide for the appropriate use of breath testing. Dig Dis Sci 2021;66:338–347.CrossRefPubMed Massey BT, Wald A. Small intestinal bacterial overgrowth syndrome: a guide for the appropriate use of breath testing. Dig Dis Sci 2021;66:338–347.CrossRefPubMed
6.
go back to reference Erdogan A, Rao SS, Gulley D et al. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil 2015;27:481–489.CrossRefPubMed Erdogan A, Rao SS, Gulley D et al. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil 2015;27:481–489.CrossRefPubMed
7.
go back to reference Rezaie A, Buresi M, Lembo A et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus. Am J Gastroenterol 2017;112:775–784.CrossRefPubMedPubMedCentral Rezaie A, Buresi M, Lembo A et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus. Am J Gastroenterol 2017;112:775–784.CrossRefPubMedPubMedCentral
8.
go back to reference Cangemi DJ, Lacy BE, Wise J. Diagnosing small intestinal bacterial overgrowth: a comparison of lactulose breath tests to small bowel aspirates. Dig Dis Sci. 2021;66:2042–2050.CrossRefPubMed Cangemi DJ, Lacy BE, Wise J. Diagnosing small intestinal bacterial overgrowth: a comparison of lactulose breath tests to small bowel aspirates. Dig Dis Sci. 2021;66:2042–2050.CrossRefPubMed
9.
go back to reference Enko D, Kriegshäuser G. Functional 13C-urea and glucose hydrogen/methane breath tests reveal significant association of small intestinal bacterial overgrowth in individuals with active Helicobacter pylori infection. Clin Biochem 2017;50:46–49.CrossRefPubMed Enko D, Kriegshäuser G. Functional 13C-urea and glucose hydrogen/methane breath tests reveal significant association of small intestinal bacterial overgrowth in individuals with active Helicobacter pylori infection. Clin Biochem 2017;50:46–49.CrossRefPubMed
10.
go back to reference Del Zompo F, Ojetti V, Feliciani D et al. Helicobacter pylori infection is associated with high methane production during lactulose breath test. Eur Rev Med Pharmacol Sci 2016;20:3452–3456.PubMed Del Zompo F, Ojetti V, Feliciani D et al. Helicobacter pylori infection is associated with high methane production during lactulose breath test. Eur Rev Med Pharmacol Sci 2016;20:3452–3456.PubMed
11.
go back to reference Zhou M, Wang AM, Wang JK, Jia SJ. Relationship between Helicobacter pylori related peptic ulcer and small intestinal bacterial overgrowth. Chin J Gastroenterol Hepatol 2013;22:60–61. Zhou M, Wang AM, Wang JK, Jia SJ. Relationship between Helicobacter pylori related peptic ulcer and small intestinal bacterial overgrowth. Chin J Gastroenterol Hepatol 2013;22:60–61.
12.
go back to reference Liu WZ, Xie Y, Lu H et al. Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori and peptic ulcer. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter 2018;23:e12475.CrossRefPubMed Liu WZ, Xie Y, Lu H et al. Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori and peptic ulcer. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter 2018;23:e12475.CrossRefPubMed
13.
go back to reference Su T, Lai S, Lee A, He X, Chen S. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol 2018;53:27–36.CrossRefPubMed Su T, Lai S, Lee A, He X, Chen S. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol 2018;53:27–36.CrossRefPubMed
15.
go back to reference Smolka AJ, Schubert ML. Helicobacter pylori-induced changes in gastric acid secretion and upper gastrointestinal disease. Curr Top Microbiol Immunol 2017;400:227–252.PubMed Smolka AJ, Schubert ML. Helicobacter pylori-induced changes in gastric acid secretion and upper gastrointestinal disease. Curr Top Microbiol Immunol 2017;400:227–252.PubMed
16.
go back to reference Dharan M, Wozny D. Helicobacter pylori infection and small intestinal bacterial overgrowth-more than what meets the eye. World J Clin Cases 2022;10:7209–7214.CrossRefPubMedPubMedCentral Dharan M, Wozny D. Helicobacter pylori infection and small intestinal bacterial overgrowth-more than what meets the eye. World J Clin Cases 2022;10:7209–7214.CrossRefPubMedPubMedCentral
17.
go back to reference Suzuki H, Moayyedi P. Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013;10:168–174.CrossRefPubMed Suzuki H, Moayyedi P. Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013;10:168–174.CrossRefPubMed
18.
go back to reference Lopetuso LR, Scaldaferri F, Franceschi F, Gasbarrini A. The gastrointestinal microbiome-functional interference between stomach and intestine. Best Pract Res Clin Gastroenterol 2014;28:995–1002.CrossRefPubMed Lopetuso LR, Scaldaferri F, Franceschi F, Gasbarrini A. The gastrointestinal microbiome-functional interference between stomach and intestine. Best Pract Res Clin Gastroenterol 2014;28:995–1002.CrossRefPubMed
19.
go back to reference Heimesaat MM, Fischer A, Plickert R et al. Helicobacter pylori induced gastric immunopathology is associated with distinct microbiota changes in the large intestines of long-term infected Mongolian gerbils. PLoS ONE 2014;9:e100362.CrossRefPubMedPubMedCentral Heimesaat MM, Fischer A, Plickert R et al. Helicobacter pylori induced gastric immunopathology is associated with distinct microbiota changes in the large intestines of long-term infected Mongolian gerbils. PLoS ONE 2014;9:e100362.CrossRefPubMedPubMedCentral
20.
go back to reference Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 2017;45:604–616.CrossRefPubMedPubMedCentral Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 2017;45:604–616.CrossRefPubMedPubMedCentral
21.
go back to reference Lauritano EC, Gabrielli M, Scarpellini E et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci 2009;13:111–116.PubMed Lauritano EC, Gabrielli M, Scarpellini E et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci 2009;13:111–116.PubMed
22.
go back to reference Attar A, Flourié B, Rambaud JC et al. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 1999;117:794–797.CrossRefPubMed Attar A, Flourié B, Rambaud JC et al. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 1999;117:794–797.CrossRefPubMed
23.
go back to reference Konrad P, Chojnacki J, Gąsiorowska A et al. Therapeutic efficacy of amoxicillin and rifaximin in patients with small intestinal bacterial overgrowth and Helicobacter pylori infection. Prz Gastroenterol 2018;13:213–217.PubMedPubMedCentral Konrad P, Chojnacki J, Gąsiorowska A et al. Therapeutic efficacy of amoxicillin and rifaximin in patients with small intestinal bacterial overgrowth and Helicobacter pylori infection. Prz Gastroenterol 2018;13:213–217.PubMedPubMedCentral
24.
go back to reference Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut 2015;64:1049–1057.CrossRefPubMed Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut 2015;64:1049–1057.CrossRefPubMed
25.
go back to reference Yazdanbod A, Salimian S, Habibzadeh S et al. Effect of Helicobacter pylori eradication in Iranian patients with functional dyspepsia: a prospective, randomized, placebo-controlled trial. Arch Med Sci 2015;11:964–969.PubMedPubMedCentral Yazdanbod A, Salimian S, Habibzadeh S et al. Effect of Helicobacter pylori eradication in Iranian patients with functional dyspepsia: a prospective, randomized, placebo-controlled trial. Arch Med Sci 2015;11:964–969.PubMedPubMedCentral
26.
go back to reference Zhao W, Zhong X, Zhuang X et al. Evaluation of Helicobacter pylori eradication and drug therapy in patients with functional dyspepsia. Exp Ther Med 2013;6:37–44.CrossRefPubMedPubMedCentral Zhao W, Zhong X, Zhuang X et al. Evaluation of Helicobacter pylori eradication and drug therapy in patients with functional dyspepsia. Exp Ther Med 2013;6:37–44.CrossRefPubMedPubMedCentral
27.
go back to reference Sodhi JS, Javid G, Zargar SA et al. Prevalence of Helicobacter pylori infection and the effect of its eradication on symptoms of functional dyspepsia in Kashmir, India. J Gastroenterol Hepatol 2013;28:808–813.CrossRefPubMed Sodhi JS, Javid G, Zargar SA et al. Prevalence of Helicobacter pylori infection and the effect of its eradication on symptoms of functional dyspepsia in Kashmir, India. J Gastroenterol Hepatol 2013;28:808–813.CrossRefPubMed
29.
go back to reference Tan VP, Liu KS, Lam FY et al. Randomised clinical trial: rifaximin versus placebo for the treatment of functional dyspepsia. Aliment Pharmacol Ther 2017;45:767–776.CrossRefPubMed Tan VP, Liu KS, Lam FY et al. Randomised clinical trial: rifaximin versus placebo for the treatment of functional dyspepsia. Aliment Pharmacol Ther 2017;45:767–776.CrossRefPubMed
30.
go back to reference Lauritano EC, Gabrielli M, Scarpellini E et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol 2008;103:2031–2035.CrossRefPubMed Lauritano EC, Gabrielli M, Scarpellini E et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol 2008;103:2031–2035.CrossRefPubMed
Metadata
Title
Influence of Helicobacter pylori Infection and Eradication on Small Intestinal Bacterial Overgrowth and Abdominal Symptoms
Authors
Xiaolei Wang
Die Zhu
Siyu Li
Yun Dai
Guigen Teng
Weihong Wang
Publication date
15-02-2024
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2024
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-024-08279-y

Other articles of this Issue 4/2024

Digestive Diseases and Sciences 4/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.